UB-221Innovative Anti-IgE Monoclonal Antibody

Indication

Chronic idiopathic urticaria (CIU)

Stage

Phase I clinical trial

Global Prevalence Rate/Patient Number

There are 375 million people who has urticaria in 2016 (two-thirds of the cases are CIU)(WHO); About 1.5 million people in the US has CIU

Global Market Size

The market size of allergy medication in 2016 was $5.2B; global sales of Xolair® was $2.3B

  • What is UB-221

    UB-221 is a 3rd generation anti-IgE monoclonal antibody drug for treating patients with IgE-mediated allergic diseases.

  • Mechanism

    UB-221 is a humanized mAb that can both neutralize free IgE and down-regulate IgE synthesis via CD23 on B cells.

  • Advantages

    1. UB-221 neutralizes free IgE more effectively than Xolair® with a binding affinity 8-fold higher than that of Xolair®.
    2. UB-221 not only neutralizes free IgE but also down-regulates IgE synthesis through CD23 on B cells.